Serum 25-Hydroxyvitamin D Level and Breast Cancer Risk in Egyptian Females

Vitamin D has potent antiproliferative, prodifferentiative, and immune-modulatory effects. Vitamin D deficiency has been suggested to be very prevalent and there is growing evidence for the association between vitamin D deficiency and risk of breast cancer. The aim of this study was to evaluate the association of serum 25-hydroxyvitamin D [25(OH)D] level with breast cancer risk among Egyptian women. The current study included 40 breast cancer cases and 40 healthy control women. Serum 25(OH)D levels were measured using enzyme-linked immunosorbent assay for all women and together with other clinical factors were correlated to the risk of breast cancer. A total of 80 women including 40 breast cancer cases and 40 controls were included in this analysis. The clinical characteristics were well balanced with no significant difference between cases and controls regarding age, menopausal status, weight, height, body mass index, serum calcium, and phosphorus levels. The mean serum 25(OH)D level in cases (12.11 ng/mL) was significantly lower than in controls (19.77 ng/mL). Ninety percent of cases had 25(OH)D deficiency (<20 ng/mL) compared with 57.5% of the controls. After adjustment for potentially confounding variables, women with vitamin D deficiency were associated with a high significant risk of breast cancer compared to women with sufficient vitamin D with OR of 6.99 (95% CI = 2.01–24.32, p = 0.002). A significant association exists between vitamin D deficiency and the risk of breast cancer in Egyptian women.